Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Graham Osborn who wrote (55438)	6/9/2015 12:51:12 PM
From: E_K_S	Read Replies (3) of 78731

ANI Pharmaceuticals, Inc. (ANIP) Have you looked at ANIP? I have been watching this one specifically for their branded and generic prescription pharmaceuticals. They have a lot less debt that TARO and meet the Buffet debt requirements (4x Net income <= LT debt). Company is still small at $622mln market cap. ANIP pays no dividend. I have no position yet but have an order to start a position at/below $50.00/share. I like the sector. I have been watching both Mylan and TARO but decided I like ANIP better. EKS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next